OBJECTIVES: Sinonasal and skull base tumors comprise a heterogeneous group of malignancies with a significant rate of distant recurrence (DR). The aim of this study was to analyze tumor and host factors, including pretreatment neutrophil-to-lymphocyte ratio (NLR), that predict DR in these patients. MATERIALS AND METHODS: We retrospectively reviewed sinonasal tumors and/or tumors involving the skull base treated with surgery between 1973 and 2015 (n = 473). We stratified NLR using the top 5 percentile as cutoff. Factors predictive of outcome were determined by Cox proportional hazards model. RESULTS: Most tumors were primary (81%) and 67% had skull base resection. The most common site was the nasal cavity (37%) and the most common histology was squamous cell carcinoma (34%). Most patients presented with advanced primary tumor stage (pT3/T4; 80%) and most had no regional neck disease (pNx/N0; 93%). A total of 104 patients developed DR. The 5-year overall and disease-specific survival for patients who developed DR were 36.4% and 35.8%, compared to 69.0% and 74.9% for patients who did not. Patients with DR had a higher percentage of NLR-high patients compared patients without DR (11% vs 3%, p = .006). In a multivariable analysis, melanoma histology (HR = 5.469, 95% CI 3.171-9.433), pT3/T4 (HR = 2.686, 95% CI 1.150-6.275), pN+ (HR = 6.864, 95% CI 3.450-13.653), and NLR-high (HR = 3.489, 95% CI 1.593-7.639) were independent predictors of DR. CONCLUSION: Melanoma histology, pT, pN, and high NLR predict DR, suggesting that both tumor and host factors need to be considered. NLR may act as a surrogate marker of the host́s immune system.
OBJECTIVES: Sinonasal and skull base tumors comprise a heterogeneous group of malignancies with a significant rate of distant recurrence (DR). The aim of this study was to analyze tumor and host factors, including pretreatment neutrophil-to-lymphocyte ratio (NLR), that predict DR in these patients. MATERIALS AND METHODS: We retrospectively reviewed sinonasal tumors and/or tumors involving the skull base treated with surgery between 1973 and 2015 (n = 473). We stratified NLR using the top 5 percentile as cutoff. Factors predictive of outcome were determined by Cox proportional hazards model. RESULTS: Most tumors were primary (81%) and 67% had skull base resection. The most common site was the nasal cavity (37%) and the most common histology was squamous cell carcinoma (34%). Most patients presented with advanced primary tumor stage (pT3/T4; 80%) and most had no regional neck disease (pNx/N0; 93%). A total of 104 patients developed DR. The 5-year overall and disease-specific survival for patients who developed DR were 36.4% and 35.8%, compared to 69.0% and 74.9% for patients who did not. Patients with DR had a higher percentage of NLR-high patients compared patients without DR (11% vs 3%, p = .006). In a multivariable analysis, melanoma histology (HR = 5.469, 95% CI 3.171-9.433), pT3/T4 (HR = 2.686, 95% CI 1.150-6.275), pN+ (HR = 6.864, 95% CI 3.450-13.653), and NLR-high (HR = 3.489, 95% CI 1.593-7.639) were independent predictors of DR. CONCLUSION: Melanoma histology, pT, pN, and high NLR predict DR, suggesting that both tumor and host factors need to be considered. NLR may act as a surrogate marker of the host́s immune system.
Authors: Mario Turri-Zanoni; Giovanni Salzano; Alessia Lambertoni; Marta Giovannardi; Apostolos Karligkiotis; Paolo Battaglia; Paolo Castelnuovo Journal: Head Neck Date: 2016-12-29 Impact factor: 3.147
Authors: Shao Hui Huang; John N Waldron; Michael Milosevic; Xiaowei Shen; Jolie Ringash; Jie Su; Li Tong; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew J Bayley; John Kim; Andrew Hope; B C John Cho; Meredith Giuliani; Albiruni Razak; David Goldstein; Willa Shi; Fei-Fei Liu; Wei Xu; Brian O'Sullivan Journal: Cancer Date: 2014-10-21 Impact factor: 6.860
Authors: Snehal G Patel; Bhuvanesh Singh; Ashok Polluri; Patrick G Bridger; Giulio Cantu; Anthony D Cheesman; Geraldo M deSa; Paul Donald; Dan Fliss; Patrick Gullane; Ivo Janecka; Shin-Etsu Kamata; Luiz P Kowalski; Dennis H Kraus; Paul A Levine; Luiz R M dos Santos; Sultan Pradhan; Victor Schramm; Carl Snyderman; William I Wei; Jatin P Shah Journal: Cancer Date: 2003-09-15 Impact factor: 6.860
Authors: O Abu-Shawer; M Abu-Shawer; N Hirmas; A Alhouri; A Massad; B Alsibai; H Sultan; H Hammo; M Souleiman; Y Shebli; M Al-Hussaini Journal: BMC Cancer Date: 2019-02-12 Impact factor: 4.430
Authors: Cristina Valero; Mark Lee; Douglas Hoen; Kate Weiss; Daniel W Kelly; Prasad S Adusumilli; Paul K Paik; George Plitas; Marc Ladanyi; Michael A Postow; Charlotte E Ariyan; Alexander N Shoushtari; Vinod P Balachandran; A Ari Hakimi; Aimee M Crago; Kara C Long Roche; J Joshua Smith; Ian Ganly; Richard J Wong; Snehal G Patel; Jatin P Shah; Nancy Y Lee; Nadeem Riaz; Jingming Wang; Ahmet Zehir; Michael F Berger; Timothy A Chan; Venkatraman E Seshan; Luc G T Morris Journal: Nat Commun Date: 2021-02-01 Impact factor: 14.919